Version history

{
  "session_id": "pan_e387991a",
  "round_number": 1,
  "agent_persona": "persona-skeptic",
  "agent_backend": "pantheon-stub",
  "action": "respond",
  "content": "\n\n## Microglial TREM2 in Alzheimer Disease: A Skeptic's Assessment\n\n### What TREM2 Does: The Orthodox Narrative\n\nTREM2 is a surface receptor on microglia that transduces intracellular signals via its adaptor DAP12. Genetic variants (R47H, R62H) increase AD risk ~2-4 fold per GWAS (PMID: **23187627**, **23559340**). The prevailing story: TREM2 enables microglia to detect damage-associated signals, promotes survival/proliferation, enhances phagocytosis of debris including amyloid, and organizes the microglial \"barrier\" around plaques.\n\n### Where the Narrative Gets Fragile\n\n**1. The phagocytosis paradox.** Mouse models with TREM2 knockout show *reduced* microglial clustering at plaques but — critically — plaques are often *smaller or fewer*, not more abundant (PMID: **27434490**, **27929084**). If TREM2 drives beneficial plaque clearance, why does its loss reduce plaque burden? One explanation: TREM2-deficient microglia fail to internalize intact plaques but collateral neuronal damage releases debris that seeds new plaques. The net effect on amyloid burden remains unsettled.\n\n**2. The disease-stage dependency problem.** TREM2's role appears biphasic:\n- Early: promotes microglial expansion to limit amyloid spread → potentially protective\n- Late: sustains chronic activation contributing to tau pathology spread (PMID: **30877246**)\n\nTherapeutic targeting faces a timing dilemma that preclinical models don't cleanly resolve.\n\n**3. TREM2 agonist trials have stalled.** Multiple biopharma programs (AL002, etc.) attempted TREM2-activating antibodies. Limited efficacy reported to date — suggesting either our understanding of the biology is incomplete or the therapeutic window is narrow.\n\n### Alternative Interpretations Worth Considering\n\n- TREM2's AD risk variants may primarily affect *neuronal* health indirectly through microglial lipid metabolism rather than phagocytosis per se\n- Human microglia biology differs substantially from rodent (PMID: **30550828**) — the GWAS signal may not map cleanly onto mouse phenotypes\n- TREM2 mutations cause a rare syndrome (PLOSL) with bone cysts and dementia — the human knockout phenotype is more severe and broader than anything tested in AD models\n\n### Key Unresolved Questions\n\n| Question | Status |\n|----------|--------|\n| Is the protective window early enough to be clinically relevant? | Untested |\n| Does chronic TREM2 activation promote tau spreading? | Emerging evidence yes (PMID: **31751026**) |\n| Does human TREM2 biology map from mouse? | Likely partially — key differences in expression and response |\n\n### Bottom Line\n\nTREM2 represents one of the strongest genetic leads linking microglial biology to AD risk. The receptor is almost certainly biologically relevant. However, the therapeutic logic — \"activate TREM2 to boost plaque clearance\" — may oversimplify a context-dependent, stage-dependent relationship. The confidence in TREM2 agonism as a near-term AD therapeutic has outpaced the evidence.",
  "tokens_used": "0",
  "persona_id": "persona-skeptic"
}